-
公开(公告)号：US20050191248A1
公开(公告)日：2005-09-01
申请号：US11006907
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61B17/68 , A61C5/00 , A61F2/00 , A61F2/28 , A61F13/00 , A61K31/045 , A61K31/4745 , A61K31/513 , A61K31/525 , A61K31/65 , A61K31/70 , A61K31/7012 , A61K31/704 , A61K31/7048 , A61K31/7072 , A61K31/765 , A61K33/14 , A61K33/24 , A61K38/17 , A61K38/18 , A61K38/19 , A61K38/20 , A61K38/24 , A61K38/39 , A61K38/48 , A61K49/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61K7/28
CPC分类号： A61L27/54 , A61B17/11 , A61B17/12022 , A61B17/12099 , A61B17/12109 , A61B17/1214 , A61B17/12168 , A61B17/12186 , A61B17/1219 , A61B17/68 , A61F2250/0067 , A61K38/363 , A61K38/38 , A61K38/39 , A61K38/4833 , A61K45/06 , A61L31/16 , A61L2300/00 , A61L2300/412 , A61L2430/38 , A61K2300/00
摘要： Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
-
公开(公告)号：US20050177225A1
公开(公告)日：2005-08-11
申请号：US11006895
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61F2/00 , A61F2/02 , A61F2/04 , A61F2/06 , A61F2/28 , A61F2/44 , A61K38/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M16/04 , A61M31/00 , A61N1/05 , A62B9/00
CPC分类号： A61L31/16 , A61B17/11 , A61B17/12022 , A61B17/1219 , A61F2250/0067 , A61L2300/404 , A61L2300/406 , A61L2300/416 , A61L2300/426 , A61L2300/432 , A61N1/05
摘要： Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
-
公开(公告)号：US20050169959A1
公开(公告)日：2005-08-04
申请号：US11001421
申请日：2004-12-01
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61B17/68 , A61C5/00 , A61F2/00 , A61F2/28 , A61F13/00 , A61K31/045 , A61K31/4745 , A61K31/513 , A61K31/525 , A61K31/65 , A61K31/70 , A61K31/7012 , A61K31/704 , A61K31/7048 , A61K31/7072 , A61K31/765 , A61K33/14 , A61K33/24 , A61K38/17 , A61K38/18 , A61K38/19 , A61K38/20 , A61K38/24 , A61K38/39 , A61K38/48 , A61K49/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16
CPC分类号： A61L27/54 , A61B17/11 , A61B17/12022 , A61B17/12099 , A61B17/12109 , A61B17/1214 , A61B17/12168 , A61B17/12186 , A61B17/1219 , A61B17/68 , A61F2250/0067 , A61K38/363 , A61K38/38 , A61K38/39 , A61K38/4833 , A61K45/06 , A61L31/16 , A61L2300/00 , A61L2300/412 , A61L2430/38 , A61K2300/00
摘要： Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
-
公开(公告)号：US20050149173A1
公开(公告)日：2005-07-07
申请号：US10986450
申请日：2004-11-10
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
IPC分类号： A61B17/00 , A61B17/11 , A61B17/12 , A61F2/00 , A61F2/86 , A61F13/00 , A61K38/48 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M29/00 , A61M31/00 , A61F2/06
CPC分类号： A61B17/12172 , A61B17/00491 , A61B17/11 , A61B17/12022 , A61B17/12045 , A61B17/12136 , A61B17/1215 , A61B17/12177 , A61B17/12186 , A61B17/1219 , A61B2017/00004 , A61F2/86 , A61F2250/0067 , A61L31/16 , A61L2300/412
摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
-
公开(公告)号：US20050186247A1
公开(公告)日：2005-08-25
申请号：US11006904
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61B17/68 , A61C5/00 , A61F2/00 , A61F2/28 , A61F13/00 , A61K31/045 , A61K31/4745 , A61K31/513 , A61K31/525 , A61K31/65 , A61K31/70 , A61K31/7012 , A61K31/704 , A61K31/7048 , A61K31/7072 , A61K31/765 , A61K33/14 , A61K33/24 , A61K38/17 , A61K38/18 , A61K38/19 , A61K38/20 , A61K38/24 , A61K38/39 , A61K38/48 , A61K49/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16
CPC分类号： A61L27/54 , A61B17/11 , A61B17/12022 , A61B17/12099 , A61B17/12109 , A61B17/1214 , A61B17/12168 , A61B17/12186 , A61B17/1219 , A61B17/68 , A61F2250/0067 , A61K38/363 , A61K38/38 , A61K38/39 , A61K38/4833 , A61K45/06 , A61L31/16 , A61L2300/00 , A61L2300/412 , A61L2430/38 , A61K2300/00
摘要： Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
-
公开(公告)号：US20050186243A1
公开(公告)日：2005-08-25
申请号：US11000097
申请日：2004-11-29
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
IPC分类号： A61B17/00 , A61B17/11 , A61B17/12 , A61F2/00 , A61F2/86 , A61F13/00 , A61K38/48 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M29/00 , A61M31/00
CPC分类号： A61B17/12172 , A61B17/00491 , A61B17/11 , A61B17/12022 , A61B17/12045 , A61B17/12136 , A61B17/1215 , A61B17/12177 , A61B17/12186 , A61B17/1219 , A61B2017/00004 , A61F2/86 , A61F2250/0067 , A61L31/16 , A61L2300/412
摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
-
公开(公告)号：US20050183728A1
公开(公告)日：2005-08-25
申请号：US11007836
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61F2/00 , A61F2/02 , A61F2/04 , A61F2/06 , A61F2/28 , A61F2/44 , A61K38/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M16/04 , A61M31/00 , A61N1/05 , A62B9/00
CPC分类号： A61L31/16 , A61B17/11 , A61B17/12022 , A61B17/1219 , A61F2250/0067 , A61L2300/404 , A61L2300/406 , A61L2300/416 , A61L2300/426 , A61L2300/432 , A61N1/05
摘要： Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
-
公开(公告)号：US20050181011A1
公开(公告)日：2005-08-18
申请号：US11001792
申请日：2004-12-02
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61F2/00 , A61F2/02 , A61F2/04 , A61F2/06 , A61F2/28 , A61F2/44 , A61K38/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M16/04 , A61M31/00 , A61N1/05 , A62B9/00
CPC分类号： A61L31/16 , A61B17/11 , A61B17/12022 , A61B17/1219 , A61F2250/0067 , A61L2300/404 , A61L2300/406 , A61L2300/416 , A61L2300/426 , A61L2300/432 , A61N1/05
摘要： Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
-
公开(公告)号：US20050181004A1
公开(公告)日：2005-08-18
申请号：US11006289
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
IPC分类号： A61B17/00 , A61B17/11 , A61B17/12 , A61F2/00 , A61F2/86 , A61F13/00 , A61K38/48 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M29/00 , A61M31/00
CPC分类号： A61B17/12172 , A61B17/00491 , A61B17/11 , A61B17/12022 , A61B17/12045 , A61B17/12136 , A61B17/1215 , A61B17/12177 , A61B17/12186 , A61B17/1219 , A61B2017/00004 , A61F2/86 , A61F2250/0067 , A61L31/16 , A61L2300/412
摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
-
公开(公告)号：US20050165467A1
公开(公告)日：2005-07-28
申请号：US11006048
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
IPC分类号： A61B17/00 , A61B17/11 , A61B17/12 , A61F2/00 , A61F2/86 , A61F13/00 , A61K38/48 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M29/00 , A61M31/00 , A61F2/06
CPC分类号： A61B17/12172 , A61B17/00491 , A61B17/11 , A61B17/12022 , A61B17/12045 , A61B17/12136 , A61B17/1215 , A61B17/12177 , A61B17/12186 , A61B17/1219 , A61B2017/00004 , A61F2/86 , A61F2250/0067 , A61L31/16 , A61L2300/412
摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
-
-
-
-
-
-
-
-
-
搜索结果
102 条记录 (耗时 0.118 秒)
